KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Cash from Investing Activities data on record, last reported at -$55.9 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 145.74% year-over-year to -$55.9 million; the TTM value through Dec 2025 reached -$302.6 million, down 890.78%, while the annual FY2025 figure was -$302.6 million, 890.78% down from the prior year.
  • Cash from Investing Activities reached -$55.9 million in Q4 2025 per ACAD's latest filing, up from -$79.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $192.5 million in Q1 2023 and bottomed at -$194.3 million in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$14.9 million, with a median of -$17.5 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: soared 35301.73% in 2024, then crashed 783.6% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $71.5 million in 2021, then plummeted by 124.81% to -$17.7 million in 2022, then skyrocketed by 98.04% to -$347000.0 in 2023, then skyrocketed by 35301.73% to $122.2 million in 2024, then tumbled by 145.74% to -$55.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$55.9 million in Q4 2025, -$79.4 million in Q3 2025, and -$43.3 million in Q2 2025.